Previous 10 | Next 10 |
Turning Point Therapeutics, Inc. (TPTX) Q3 2021 Results Earnings Conference Call November 10, 2021, 04:30 PM ET Company Participants Adam Levy - Senior Vice President of Investor Relations Athena Countouriotis - President and Chief Executive Officer Paolo Tombesi - Executive Vice President an...
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Adam Levy, Ph.D., MBA, as senior vice president of Invest...
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will report third quarter financial results following the close of U...
Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations Repotrectinib Demonstrated Confirmed Responses in 3 of 4 TKI-Naïve Patients SAN DIEGO, Oct. 23, 2021...
SAN DIEGO, Calif. and CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of pharmaceutical company committed to dev...
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will present early clinical data for repotrectinib from the ongoing ...
While the S&P 500 index eked out a ~0.8% gain over the week, its healthcare constituents slipped ~0.3% to record the fifth consecutive weekly loss. Dragged down by biotech stocks, the sector became the second-worst performer in the index. Among healthcare stocks with more than $...
Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid Tumors Confirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with Solvent Front Mutations ...
Gainers: Camber Energy (NYSE:CEI) +97%. Merus (NASDAQ:MRUS) +32%. New Fortress Energy (NASDAQ:NFE) +25%. Paltalk (NASDAQ:PALT) +25%. Grom Social Enterprises (NASDAQ:GROM) +20%. DatChat (NASDAQ:DATS) +20%. Jupiter Wellness (NASDAQ:JUPW) +18%. NextPlay Technologies (NASDAQ:NXTP) +19%. Independe...
Gainers: Merus (NASDAQ:MRUS) +36%, Nutriband (OTCQB:NTRB) +16%, Skylight Health (NASDAQ:SLHG) +16%, Rani Therapeutics (NASDAQ:RANI) +12%, Jupiter Wellness (NASDAQ:JUPW) +12%. Losers: Osmotica Pharmaceuticals (NASDAQ:OSMT) -38%, Prelude Therapeutics (NAS...
News, Short Squeeze, Breakout and More Instantly...
Turning Point Therapeutics Inc. Company Name:
TPTX Stock Symbol:
NYSE Market:
Turning Point Therapeutics Inc. Website:
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the recei...
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET...
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced receipt of positive feedback from the U.S. Food and Drug Administ...